Mitochondrial structural and functional dynamics in Huntington's disease

Brain Research Reviews

Volumn 61, Issue 1, 2009, Pages 33-48

  Reddy, P Hemachandra ^a,b   Mao, Peizhong ^a   Manczak, Maria ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Calcium dyshomeostasis; Dimebon; Huntington's Disease; Mitochondria; Mitochondrial dynamics; Polyglutamine repeat

Indexed keywords

CREATINE; DIMEBON; HUNTINGTIN; MITOCHONDRIAL DNA; MUTANT PROTEIN; RESVERATROL; UBIDECARENONE;

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; BIOENERGY; BRAIN MITOCHONDRION; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CELL VACUOLE; CENTRAL NERVOUS SYSTEM; CHOREA; CLINICAL TRIAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG MEGADOSE; HUMAN; HUNTINGTON CHOREA; INVOLUNTARY MOVEMENT; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION; TRINUCLEOTIDE REPEAT;

ANIMALS; DNA, MITOCHONDRIAL; HUMANS; HUNTINGTON DISEASE; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; TRINUCLEOTIDE REPEATS;

EID: 67349247037     PISSN: 01650173     EISSN: 18726321     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2009.04.001     Document Type: Review

References (129)

1. Acevedo-Torres K., Berríos L., Rosario N., Dufault V., Skatchkov S., Eaton M.J., Torres-Ramos C.A., and Ayala-Torres S. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease. DNA Repair (Amst). 8 (2009) 126-136
2. Andreassen O.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., Thomas M., Friedlich A., Browne S.E., Schilling G., Borchelt D.R., Hersch S.M., and Ross C.A. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 8 (2001) 479-491
3. Anekonda T.S., and Reddy P.H. Neuronal protection by sirtuins in Alzheimer's disease. J. Neurochem. 96 (2006) 305-313
4. Atwal R.S., Xia J., Pinchev D., Taylor J., Epand R.M., and Truant R. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum. Mol. Genet. 16 (2007) 2600-2615
5. Aylward E.H., Brandt J., Codori A.M., et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 44 (1994) 823-828
6. Aylward E.H., Li Q., Stine O., et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 48 (1997) 394-399
7. Aylward E.H., Anderson N.B., Bylsma F.W., et al. Frontal lobe volume in patients with Huntington's disease. Neurology 50 (1998) 252-258
8. Aziz N.A., van der Burg J.M., Landwehrmeyer G.B., Brundin P., Stijnen T., Roos R.A., and EHDI Study Group. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71 (2008) 1506-1513
9. Bachurin S., Bukatina E., Lermontova N., Tkachenko S., Afanasiev A., Grigoriev V., Grigorieva I., Ivanov Y., Sabli S., and Zefirov N. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann. N.Y. Acad. Sci. 939 (2001) 425-435
10. Bachurin S.O., Shevtsova E.P., Kireeva E.G., Oxenkrug G.F., and Sablin S.O. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann. N.Y. Acad. Sci. 993 (2003) 334-344
11. Bäckman L., Robins-Wahlin T.B., Lundin A., et al. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 120 (1997) 2207-2217
12. Bamford K.A., Caine E.D., Kido D.K., et al. Clinical-pathologic correlation in Huntington's disease: a neuropsychological and computed tomography study. Neurology 39 (1989) 796-801
13. Banoei M.M., Houshmand M., Panahi M.S., Shariati P., Rostami M., Manshadi M.D., and Majidizadeh T. Huntington's disease and mitochondrial DNA deletions: event or regular mechanism for mutant huntingtin protein and CAG repeats expansion?!. Cell. Mol. Neurobiol. 27 (2007) 867-875
14. Bates G.P. History of genetic disease: the molecular genetics of Huntington disease - a history. Nat. Rev., Genet. 6 (2005) 766-773
15. Berent S., Giordani B., Lehtinen S., et al. Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function. Ann. Neurol. 23 (1998) 541-546
16. Boudreau R.L., McBride J.L., Martins I., Shen S., Xing Y., Carter B.J., and Davidson B.L. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther. (2009) 2009 Feb 24. [electronic publication ahead of print]
17. Borrell-Pagès M., Zala D., Humbert S., and Saudou F. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell. Mol. Life Sci. 63 (2006) 2642-2660
18. Bossy-Wetzel E., Petrilli A., and Knott A.B. Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci. 31 (2008) 609-616
19. Browne S.E. Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Ann. N. Y. Acad. Sci. 1147 (2008) 358-382
20. Browne S.E., and Beal M.F. The energetics of Huntington's disease. Neurochem Res. 29 (2004) 531-546
21. Browne S.E., and Beal M.F. Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox. Signal. 8 (2006) 2061-2073
22. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., and Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41 (1997) 646-653
23. Byers R.K., Gilles F.H., and Fung C. Huntington's disease in children. Neuropathologic study of four cases. Neurology 23 (1973) 561-569
24. Centonze D., Gubellini P., Picconi B., Saulle E., Tolu M., Bonsi P., Giacomini P., and Calabresi P. An abnormal striatal synaptic plasticity may account for the selective neuronal vulnerability in Huntington's disease. Neurol. Sci. 22 (2001) 61-62
25. Chan D.C. Mitochondrial fusion and fission in mammals. Annu. Rev. Cell Dev. Biol. 22 (2006) 79-99
26. Chang D.T., Rintoul G.L., Pandipati S., and Reynolds I.J. Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol. Dis. 22 (2006) 388-400
27. Charles V., Mezey E., Reddy P.H., Dehejia A., Young T.A., Polymeropoulos M.H., Brownstein M.J., and Tagle D.A. Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models. Neurosci. Lett. 289 (2000) 29-32
28. Chen C.M., Wu Y.R., Cheng M.L., Liu J.L., Lee Y.M., Lee P.W., Soong B.W., and Chiu D.T. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochem. Biophys. Res. Commun. 359 (2007) 335-340
29. Choo Y.S., Johnson G.V., MacDonald M., Detloff P.J., and Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 13 (2004) 1407-1420
30. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., and Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127 (2006) 59-69
31. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., and Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 (1997) 537-548
32. Dierks T., Linden D.E., Hertel A., et al. Multimodal imaging of residual function and compensatory resource allocation in cortical atrophy: a case study of parietal lobe function in a patient with Huntington's disease. Psychiatry Res. 90 (1999) 67-75
33. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., and Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277 (1997) 1990-1993
34. DiFiglia M., Sena-Esteves M., Chase K., Sapp E., Pfister E., Sass M., Yoder J., Reeves P., Pandey R.K., Rajeev K.G., Manoharan M., Sah D.W., Zamore P.D., and Aronin N. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 17204-17209
35. Doody R.S., Gavrilova S.I., Sano M., Thomas R.G., Aisen P.S., Bachurin S.O., Seely L., Hung D., and Dimebo Investigators. Effect of Dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372 (2008) 207-215
36. Faber P.W., Alter J.R., MacDonald M.E., and Hart A.C. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 179-184
37. Fennema-Notestine C., Archibald S.L., Jacobson M.W., Corey-Bloom J., Paulsen J.S., Peavy G.M., Gamst A.C., Hamilton J.M., Salmon D.P., and Jernigan T.L. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology 63 (2004) 989-995
38. Fernandes H.B., Baimbridge K.G., Church J., Hayden M.R., and Raymond L.A. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA induced apoptosis in YAC128 model of Huntington's disease. J. Neurosci. 27 (2007) 13614-13623
39. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., and Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20 (2000) 4389-4397
40. Folstein S.E. Huntington's Disease (1990), Johns Hopkins University Press
41. Fukui H., and Moraes C.T. Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates. Hum. Mol. Genet. 16 (2007) 783-797
42. 2+ in transgenic Huntington disease rats. J. Biol. Chem. 283 (2008) 30715-30724
43. Gusella J.F., Wexler N.S., Conneally P.M., Naylor S.L., Anderson M.A., Tanzi R.E., Watkins P.C., Ottina K., Wallace M.R., Sakaguchi A.Y., et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306 (1983) 234-238
44. Hamilton J.M., Wolfson T., Peavy G.M., Jacobson M.W., Corey-Bloom J., Harris G.J., Aylward E.H., Peyser C.E., et al., Huntington Study Group. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. Arch. Neurol. 53 (1996) 316-324
45. Hamilton J.M., Wolfson T., Peavy G.M., Jacobson M.W., Corey-Bloom J., and Huntington Study Group. Rate and correlates of weight change in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 75 (2004) 209-212
46. Harper S.Q., Staber P.D., He X., Eliason S.L., Martins I.H., Mao Q., Yang L., Kotin R.M., Paulson H.L., and Davidson B.L. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 5820-5825
47. Harris G.J., Aylward E.H., Peyser C.E., Brandt J., Roberts-Twillie J.V., Barta P.E., and Folstein S.E. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. Arch. Neurol. 53 (1996) 316-324
48. Hayden M.R., Martin W.R., Stoessl A.J., et al. Positron emission tomography in the early diagnosis of Huntington's disease. Neurology 36 (1986) 888-894
49. Hermel E., Gafni J., Propp S.S., Leavitt B.R., Wellington C.L., Young J.E., Hackam A.S., Logvinova A.V., Peel A.L., Chen S.F., Hook V., Singaraja R., Krajewski S., Goldsmith P.C., Ellerby H.M., Hayden M.R., Bredesen D.E., and Ellerby L.M. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ. 11 (2004) 424-438
50. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Jamot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., and Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23 (1999) 181-192
51. Huang C.C., Faber P.W., Persichetti F., Mittal V., Vonsattel J.P., MacDonald M.E., and Gusella J.F. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat. Cell Mol. Genet. 24 (1998) 217-233
52. Jackson G.R., Salecker I., Dong X., Yao X., Arnheim N., Faber P.W., MacDonald M.E., and Zipursky S.L. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 21 (1998) 633-642
53. Jana N.R., Zemskov E.A., Wang G.H., and Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 10 (2001) 1049-1059
54. Jernigan T.L., Salmon D.P., Butters N., et al. Cerebral structure on MRI, part II: specific changes in Alzheimer's and Huntington's diseases. Biol. Psychiatry 29 (1991) 68-81
55. Kegel K.B., Meloni A.R., Yi Y., Kim Y.J., Doyle E., Cuiffo B.G., Sapp E., Wang Y., Qin Z.H., Chen J.D., Nevins J.R., Aronin N., and DiFiglia M. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem. 277 (2002) 7466-7476
56. Kegel K.B., Sapp E., Yoder J., Cuiffo B., Sobin L., Kim Y.J., Qin Z.H., Hayden M.R., Aronin N., Scott D.L., Isenberg G., Goldmann W.H., and DiFiglia M. Huntingtin associates with acidic phospholipids at the plasma membrane. J. Biol. Chem. 280 (2005) 36464-36473
57. Kim M., Lee H.S., LaForet G., McIntyre C., Martin E.J., Chang P., Kim T.W., Williams M., Reddy P.H., Tagle D., Boyce F.M., Won L., Heller A., Aronin N., and DiFiglia M. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J. Neurosci. 19 (1999) 964-973
58. Kirkwood S.C., Su J.L., Conneally P., and Foroud T. Progression of symptoms in the early and middle stages of Huntington disease. Arch. Neurol. 58 (2001) 273-278
59. Kremer, B., 2002. Clinical neurology of Huntington's disease, in Huntington's Disease 3rd ed., Edited by Gillian Bates, Peter Harper and Lesley Jones.
60. Kuhl D.E., Phelps M.E., Markham C.H., et al. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann. Neurol. 12 (1982) 425-434
61. Kuwert T., Lange H.W., Langen K.J., et al. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 113 (1990) 1405-1423
62. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., Cadigan B.A., Warzecki L., Tagle D.A., Reddy P.H., Cepeda C., Calvert C.R., Jokel E.S., Klapstein G.J., Ariano M.A., Levine M.S., DiFiglia M., and Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J. Neurosci. 21 (2001) 9112-9123
63. Lee W.T., and Chang C. Magnetic resonance imaging and spectroscopy in assessing 3-nitropropionic acid-induced brain lesions: an animal model of Huntington's disease. Prog. Neurobiol. 72 (2004) 87-110
64. Lee J.M., Ivanova E.V., Seong I.S., Cashorali T., Kohane I., Gusella J.F., and MacDonald M.E. Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism. PLoS Genet. 3 8 (2007) e135
65. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., Efstratiadis A., Zeitlin S., and Chesselet M.F. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58 (1999) 515-532
66. Li S., and Li X.J. Multiple pathways contribute to the pathogenesis of Huntington disease. Mol. Neurodegener. 1 (2006) 19
67. Lim D., Fedrizzi L., Tartari M., Zuccato C., Cattaneo E., Brini M., and Carafoli E. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J. Biol. Chem. 283 (2008) 5780-5789
68. Liang H., and Ward W.F. PGC-1alpha: a key regulator of energy metabolism. Adv. Physiol. Educ. 30 (2006) 145-151
69. Lin M.T., and Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443 (2006) 787-795
70. Lin C.H., Tallaksen-Greene S., Chien W.M., Cearley J.A., Jackson W.S., Crouse A.B., Ren S., Li X.J., Albin R.L., and Detloff P.J. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 10 2 (2001) 137-144 Jan 15
71. Mahant N., McCusker E.A., Byth K., Graham S., and Huntington Study Group. Huntington's disease: clinical correlates of disability and progression. Neurology 61 (2003) 1085-1092
72. Majumder P., Raychaudhuri S., Chattopadhyay B., and Bhattacharyya N.P. Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range. Cell. Mol. Neurobiol. 27 (2007) 1127-1145
73. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
74. Marsh J.L., Walker H., Theisen H., Zhu Y.Z., Fielder T., Purcell J., and Thompson L.M. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum. Mol. Genet. 9 (2000) 13-25
75. Milakovic T., Quintanilla R.A., and Johnson G.V. Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J. Biol. Chem. 281 (2006) 34785-34795
76. Montoya A., Price B.H., Menear M., and Lepage M. Brain imaging and cognitive dysfunctions in Huntington's disease. J. Psychiatry Neurosci. 31 (2006) 21-29
77. 2+ buffering differences of intact neurons and astrocytes from cortex and striatum. J. Biol. Chem. 284 (2009) 5010-5020
78. 2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J. Neurosci. 26 (2006) 11174-11186
79. Oliveira J.M., Jekabsons M.B., Chen S., Lin A., Rego A.C., Gonçalves J., Ellerby L.M., and Nicholls D.G. Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. J. Neurochem. 101 (2007) 241-249
80. Ono T., Isobe K., Nakada K., and Hayashi J.I. Human cells are protected from mitochondrial dysfunction by complementation of DNA products in fused mitochondria. Nat. Genet. 28 (2001) 272-275
81. Orr H.T., and Zoghbi H.Y. Trinucleotide repeat disorders. Ann. Rev. Neurosci. 30 (2007) 575-621
82. Orr A.L., Li S., Wang C.E., Li H., Wang J., Rong J., Xu X., Mastroberardino P.G., Greenamyre J.T., and Li X.J. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci. 28 (2008) 2783-2792
83. Pandey M., Varghese M., Sindhu K.M., Sreetama S., Navneet A.K., Mohanakumar K.P., and Usha R. Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. J. Neurochem. 104 (2008) 420-434
84. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., and Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5 (2002) 731-736
85. 2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol. Cell. Biochem. 269 (2005) 143-152
86. Parker J.A., Arango M., Abderrahmane S., Lambert E., Tourette C., Catoire H., and Néri C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 37 (2005) 349-350
87. Perez M.K., Paulson H.L., Pendse S.J., Saionz S.J., Bonini N.M., and Pittman R.N. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J. Cell Biol. 143 (1998) 1457-1470
88. Phan J., Hickey M.A., Zhang P., Chesselet M.F., and Reue K. Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum. Mol. Genet. 18 6 (2009) 1006-1016 Mar 15
89. Powers W.J., Videen T.O., Markham J., McGee-Minnich L., Antenor-Dorsey J.V., Hershey T., and Perlmutter J.S. Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 2945-2949
90. Reddy P.H. Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. Antioxid. Redox. Signal. 9 (2007) 1647-1658
91. Reddy P.H. Mitochondrial medicine for aging and neurodegenerative diseases. Neuromol. Med. 10 (2008) 291-315
92. Reddy, P.H., in press. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp. Neurol. doi:10.1016/j.expneurol.2009.03.042.
93. Reddy P.H., and Beal M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med. 14 (2008) 45-53
94. Reddy P.H., and Tagle D.A. Biology of trinucleotide repeat disorders. In: Mattson M.P. (Ed). Genetic Aberrancies and Neurodegenerative Disorders. Advances in cell aging and gerontology Vol 3 (1999), Jai press Inc., Stanford and Connecticut
95. Reddy P.H., Williams M., Charles V., Garrett L., Pike-Buchanan L., Whetsell Jr. W.O., Miller G., and Tagle D.A. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat. Genet. 20 (1998) 198-202
96. Reddy P.H., Charles V., Williams M., Miller G., Whetsell Jr. W.O., and Tagle D.A. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Philos. Trans. R. Soc. Lond., B. Biol. Sci. 354 (1999) 1035-1045
97. Reddy P.H., Williams M., and Tagle D.A. Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci. 22 (1999) 248-255
98. Rigamonti D., Bauer J.H., De-Fraja C., Conti L., Sipione S., Sciorati C., Clementi E., Hackam A., Hayden M.R., Li Y., Cooper J.K., Ross C.A., Govoni S., Vincenz C., and Cattaneo E. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 20 (2000) 3705-3713
99. Rockabrand E., Slepko N., Pantalone A., Nukala V.N., Kazantsev A., Marsh J.L., Sullivan P.G., Steffan J.S., Sensi S.L., and Thompson L.M. The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum. Mol. Genet. 16 (2007) 61-77
100. Romero E., Cha G.H., Verstreken P., Ly C.V., Hughes R.E., Bellen H.J., and Botas J. Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron 57 (2008) 27-40
101. Sayer J.A., Manczak M., Akileswaran L., Reddy P.H., and Coghlan V.M. Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: implications for nuclear toxicity in Huntington's disease pathogenesis. Neuromol. Med. 7 (2005) 297-310
102. Schilling G., Becher M.W., Sharp A.H., et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8 (1999) 397-407
103. Schilling G., Coonfield M.L., Ross C.A., and Borchelt D.R. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. 315 (2001) 149-153
104. Senatorov V.V., Charles V., Reddy P.H., Tagle D.A., and Chuang D.M. Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington's disease. Mol. Cell. Neurosci. 22 (2003) 285-297
105. Seong I.S., Ivanova E., Lee J.M., et al. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet. 14 (2005) 2871-2880
106. Shimohata T., Nakajima T., Yamada M., et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat. Genet. 26 (2000) 29-36
107. Smith K.M., Matson S., Matson W.R., Cormier K., Del Signore S.J., Hagerty S.W., Stack E.C., Ryu H., and Ferrante R.J. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 1762 6 (2006) 616-626 Jun
108. Solans A., Zambrano A., Rodríguez M., and Barrientos A. Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum. Mol. Genet. 15 20 (2006) 3063-3081 Oct 15
109. Spargo E., Everall I.P., and Lantos P.L. Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J. Neurol. Neurosurg. Psychiatry. 56 5 (1993) 487-491 May
110. St-Pierre J., Drori S., Uldry M., et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127 (2006) 397-408
111. Strehlow A.N., Li J.Z., and Myers R.M. Wild-type huntingtin participates in protein trafficking between the Golgi and the extracellular space. Hum Mol Genet. 16 4 (2007) 391-409 Feb 15
112. Sun Y., Savanenin A., Reddy P.H., and Liu Y.F. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-d-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276 (2001) 24713-24728
113. Tabrizin S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., and Schapira A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 45 (1999) 25-32
114. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
115. Truant R., Atwal R., and Burtnik A. Hypothesis: Huntingtin may function in membrane association and vesicular trafficking. Biochem. Cell. Biol. 84 6 (2006) 912-917 Dec
116. Trushina E., Dyer R.B., Badger II J.D., Ure D., Eide L., Tran D.D., Vrieze B.T., Legendre-Guillemin V., McPherson P.S., Mandavilli B.S., Van Houten B., Zeitlin S., McNiven M., Aebersold R., Hayden M., Parisi J.E., Seeberg E., Dragatsis I., Doyle K., Bender A., Chacko C., and McMurray C.T. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell. Biol. 24 (2004) 8195-8209
117. van Bilsen P.H., Jaspers L., Lombardi M.S., Odekerken J.C., Burright E.N., and Kaemmerer W.F. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum. Gene Ther. 19 (2008) 710-719
118. Van Raamsdonk J.M., Metzler M., Slow E., Pearson J., Schwab C., Carroll J., Graham R.K., Leavitt B.R., and Hayden M.R. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol. Dis. 26 (2007) 189-200
119. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., and Richardson Jr. E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44 (1985) 559-577
120. Wang H., Lim P.J., Karbowski M., and Monteiro M.J. Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum. Mol. Genet. 18 (2009) 737-752
121. Warby S.C., Doty C.N., Graham R.K., Carroll J.B., Yang Y.Z., Singaraja R.R., Overall C.M., and Hayden M.R. Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Hum. Mol. Genet. 17 (2008) 2390-2404
122. Weydt P., Pineda V.V., Torrence A.E., et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 4 (2006) 349-362
123. Wheeler V.C., Auerbach W., White J.K., Srinidhi J., Auerbach A., Ryan A., Duyao M.P., Vrbanac V., Weaver M., Gusella J.F., Joyner A.L., and MacDonald M.E. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 8 (1999) 115-122
124. Wu J., Li Q., and Bezprozvanny I. Evaluation of Dimebon in cellular model of Huntington's disease. Mol. Neurodegener. 3 (2008) 15
125. Yamamoto A., Lucas J.J., and Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101 (2000) 57-66
126. Yang S.H., Cheng P.H., Banta H., Piotrowska-Nitsche K., Yang J.J., Cheng E.C., Snyder B., Larkin K., Liu J., Orkin J., Fang Z.H., Smith Y., Bachevalier J., Zola S.M., Li S.H., Li X.J., and Chan A.W. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 453 (2008) 921-924
127. Young A.B., Penney J.B., Starosta-Rubinstein S., et al. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann. Neurol. 20 (1986) 296-303
128. Zhang Y., Leavitt B.R., van Raamsdonk J.M., Dragatsis I., Goldowitz D., MacDonald M.E., Hayden M.R., and Friedlander R.M. Huntingtin inhibits caspase-3 activation. EMBO J. 25 (2006) 5896-5906
129. Zhang Y., Engelman J., and Friedlander R.M. Allele-specific silencing of mutant Huntington's disease gene. J. Neurochem. 108 (2009) 82-90